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Abstract: Functional selectivity is a property of G-protein-
coupled receptors (GPCRs) by which activation by 
different agonists leads to different signal transduction 
mechanisms. This phenomenon is also known as biased 
agonism and has attracted the interest of drug discovery 
programs in both academy and industry. This relatively 
recent concept has raised concerns as to the validity and 
real translational value of the results showing bias; firstly 
biased agonism may vary significantly depending on the 
cell type and the experimental constraints, secondly the 
conformational landscape that leads to biased agonism 
has not been defined. Remarkably, GPCRs may lead to 
differential signaling even when a single agonist is used. 
Here we present a concept that constitutes a biochemical 
property of GPCRs that may be underscored just using 
one agonist, preferably the endogenous agonist. “Biased 
receptor functionality” is proposed to describe this 
effect with examples based on receptor heteromerization 
and alternative splicing. Examples of regulation of final 
agonist-induced outputs based on interaction with 
b-arrestins or calcium sensors are also provided. Each of 
the functional GPCR units (which are finite in number) has 
a specific conformation. Binding of agonist to a specific 
conformation, i.e. GPCR activation, is sensitive to the 
kinetics of the agonist-receptor interactions. All these 
players are involved in the contrasting outputs obtained 
when different agonists are assayed.
Keywords: conformational landscape; GPCR heteromer; 
cytocrin; effectors; dimer; oligomer; structure. 
Introduction
Functional selectivity is triggered by binding of agonists 
interacting with residues at the orthosteric binding site that 
results in a conformational change in regions that are close 
to the intracellular domains. In silico modeling suggests 
that the second intracellular loop of the serotonin 5-HT2A 
receptor is involved in functional selectivity. The binding 
of different agonists results in different conformations of 
the intracelular loops, ultimately resulting in contrasting 
functional outputs (1). Residues in transmembrane 
domain 3 are also proposed to be important for functional 
selectivity in muscarinic (2), cannabinoid (3) and β2-
adrenergic (4) receptors. Similarly, other regions within 
the G-protein-coupled receptor (GPCR) structure may 
participate specifically in activating a given signaling 
pathway. This mini-review focuses on the biased receptor 
functionality, a phenomenon that may be underscored by 
a single agonist leading to different signaling outputs in 
different cells or even in the same cell. This phenomenon 
seemingly involves similar mechanisms to  those leading 
to biased agonism and to what is known as “system bias” 
(5–7), a concept whose definition and usefulness await 
general consensus.
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Functional selectivity or biased 
agonism: historical perspective
“Functional selectivity” and “biased agonism” can be 
used   interchangeably and can be considered synonymous 
to one another. (1,8,9). The following sentence highlights 
GPCR conformational states as the reason for biased 
agonism: “Different conformations adopted by receptors 
after associating with specific ligands can determine 
which intracellular signaling pathways get activated 
and which do not”; this sentence appears in the article 
entitled “Functional selectivity, ligand-directed trafficking, 
conformation-specific agonism: What’s in a name” (10). 
The link between biased agonism and stabilization 
of different receptor conformations leading to diverse 
signaling pathways is also reported in complementary 
reviews (11,12).
About a decade ago, functional selectivity was 
discussed by reputed scientists in the GPCR field from 
different points of view. Manuscripts related to the state 
of the question in 2007 were collected in a special issue 
in Trends in Pharmacological Science (Vol 28). One of 
these articles, “GPCR functional selectivity has therapeutic 
impact” (13), already envisaged their its potential in 
drug discovery. The term “functional selectivity” can be 
attributed to Mailman and coworkers from a publication in 
1998 on dopamine receptor subtypes (14). Reports on the 
quantitative aspects of biased agonism appeared later. The 
effects of different adrenoceptor agonists on two signaling 
responses, namely regulation of cAMP levels and MAPK 
pathway activation, were determined, and the results were 
summarized as “the results suggest that binding of different 
ligands promote distinct conformational changes leading 
to specific signaling outcomes. Our data therefore clearly 
illustrate that efficacy is a pluridimensional parameter 
that is not an intrinsic characteristic of a ligand/receptor 
couple” (15). Since then the idea of biased agonism, which 
is related to therapeutic benefits of functional selectivity, 
has gained momentum both in academia and in drug 
discovery programs in the Pharmaceutical industry 
(Figure 1). Current drug discovery programs consider 
GPCR biased agonism and have developed strategies to 
select the most effective biased compound.
Biased agonism was first “measured” by ranking the 
potency of different signaling outputs (16,17). Later, the 
“operational model“ was revisited to devise the “bias 
factor” that, for a given agonist, may be calculated by 
knowing the maximal effect and the concentration giving 
the half maximal effect, and taking both a compound and a 
given pathway as reference (7,18–21). Bias factors calculated 
in such a way do not provide all the information needed 
for pharmacological and physiological understanding of 
this singularity, i.e. they are not enough to select the most 
appropriate candidate to cure a given ailment. A summary 
Figure 1: A scheme  on functional selectivity based on differential agonist bias. Taken from (13)(fig. 2), with permission.
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of the issues surrounding the interpretation of signaling 
results, via a given receptor using different agonists, is 
provided by (22) who present a guide to properly identify 
agonists that are really biased towards a given pathway. 
More tools are needed to properly address biased agonism 
research; nowadays the most successful are based on 
a variety of “signaling” biosensors (see (23) for review). 
The “pluridimensional” view is noted by (24) as the need 
to take into account different conformations as well as 
receptor trafficking and  differential binding kinetics. 
We argue that this pluridimensional view must be 
enlarged by taking into account biochemical constraints 
related to GPCRs (receptor-receptor or receptor/
protein interactions, membrane lipid composition and 
transmembrane environment) and kinetic constraints as 
well as cytocrin-related pathways (25). However, further 
studies into ‘biased agonism’ have suggested there could 
be complications. Among other confounding factors, (22) 
suggest that results on bias agonism may be skewed due 
to “cell specific effects”. The example selected in their 
review is the case of cells overexpressing a GPCR kinase 
(GRK2) that increases β-arresting recruitment which 
can be a factor of distortion of results. Is cell specificity 
a confounding factor? Or does biased agonism depend 
on the intrinsic property of a GPCR in a given context? 
Furthermore, issues related to the actual usefulness of 
biased-agonism-guided drug development have been 
raised. These include detecting the signaling pathway of 
therapeutic interest, the cell type that should be targeted 
and how the signaling should be modulated to achieve the 
therapeutic effect (26).
Biased receptor functionality versus 
system bias
“System bias” (5–7), has been used intermittently in 
the literature and recently gained popularity (27,28). It 
stands to reason that any receptor-mediated response 
is conditioned by the system in which the signaling is 
assayed and that “system bias” likely means the bias due 
to a particular system. 
Obviously, the system “defines” the conditions, thus 
affecting signaling (qualitative and/or qualitatively). It 
appears that the final result(s) when a GPCR is activated 
by the endogenous ligand varies from cell to cell but 
also from organism to organism. For example, let us take 
epinephrine that, via cognate adrenoceptors, provokes an 
increase in the mammalian heart rate. The same hormone 
and the equivalent receptor may be expressed in organisms 
lacking a heart thus leading to other functions by similar 
and/or dissimilar mechanisms. Even in mammals, 
epinephrine and the receptor mediating the increase of 
heart rate surely have another functionality in another 
organ. For instance, in the brain, epinephrine regulates 
neurotransmission whereas in skeletal muscles it leads to 
glycogen mobilization for glucose formation and disposal. 
Actually, it is remarkable that the same molecular 
mechanism of signal transduction (increases in cAMP 
levels) may lead to different cell outputs (contractility, 
differentiation, neurotransmitter regulation, etc.) due to 
a differential cell machinery (Figure 2). Hence, a more 
general concept must be considered, one that stays 
closer to the biochemistry of GPCRs and to the proximal 
components of the signaling machinery. For that reason, 
we would like to  concentrate on signaling provided 
by a given receptor and a given agonist (preferably the 
endogenous one). In other words, we consider it relevant 
to highlight how a given receptor and a given hormone 
may lead to differential signaling (for this purpose we 
shall ignore differences in receptor functions in different 
organisms). To do so, a novel concept is needed that, in our 
opinion, should be both user-friendly and instrumental. 
We propose to name it as biased receptor functionality.
Biased receptor functionality would be defined as 
the property by which the activation of GPCRs by a single 
agonist may lead to differential engagement of signaling 
pathways. By definition, biased receptor functionality 
should be underscored by a given agonist acting on a 
given receptor but in different contexts, even in the same 
system. Two examples of “context” are shown in Figure 
2; the first is the receptor in two different locations of the 
same cell. The possibility of different activities for the same 
receptor, in two different locations of the same cell, would 
be the result of the occurrence of multiple conformations. 
Relevant but often forgotten, conformations are not 
infinite but each conformation derives from one particular 
receptor context, i.e. different conformations of a given 
GPCR in a cell reflect different contexts of the receptor (see 
below for examples).
Mechanisms underlying biased 
receptor functionality 
In our opinion, the following sentence in a seminal 
manuscript (6) encompasses biased agonism: “Seven-
transmembrane receptors are pleiotropic with respect to the 
signaling protein to which they couple in a cell, and many 
conformations of the receptor can be formed; this leads to 
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systems where ligands can stabilize unique conformations 
that go on to selectively activate signaling pathways”.
The first part of the sentence is a straightforward 
expression of the mechanism underlying functional 
selectivity that implies the vague term: “signaling 
protein”. The second part assumes that any cell could 
display many conformations of the receptor. In our 
opinion, there is consensus in that the mechanisms 
explaining bias due to the system and biased agonism are 
based on different conformations that once “stabilized” 
by an agonist lead to specific cytocrin pathways (23–25). 
Cytocrin is defined as “the (intracellular) top-down effect 
of the different molecules impacting a unicellular organism 
or a single cell” (25). The suffix “crin” as opposed to the 
suffix “crine” (as in endocrine) was coined to define the 
chain of events occurring inside a cell after a signal is 
transduced by a given receptor in a cell membrane. “Crin” 
can, therefore, be used to describe events that start near 
a membrane but go deep into the cell –cytocrin- (or into 
a cell organelle, e.g. nucleus –nucleocrin-). In terms of 
cytosolic components, the cytocrin system is constituted 
mainly by effector proteins in such a way that biased 
receptor functionality translates into different cytocrin-
mediated outputs (Figures 2-3). The underlying question 
is whether the number of conformations is limited and 
whether they are dependent on specific interactions of the 
GPCR with other proteins. 
One straightforward way to look for differential 
functional selectivity is the use of different agonists 
for a given receptor and the measure of their potency 
and maximal effect in different signaling pathways 
(G-protein-dependent, β-arrestin-dependent, etc.) 
using a cell heterologously expressing the receptor, i.e. 
after transient or stable cDNA transfection in CHO or 
HEK-293T cells. The outcome would give information 
on different conformational states that occur upon 
agonist stabilization which may lead to signaling via a 
preferential pathway (Figures 1). The output signaling 
pattern for a given GPCR is, therefore, biased/skewed 
depending on the chemical nature of the agonist used. 
Collectively, this idea is known as biased agonism and 
one may verbalize the concept by stating that agonist A 
is Gs biased, agonist B is MAPK biased, etc. In an extreme 
example, if five agonists are used and each stabilizes 
a different conformation, these five conformationally 
different receptors may (each) lead to a different signaling 
signature. However, we are more interested here in taking 
into account first what a single agonist may disclose in 
terms of receptor functionality.
Figure 2: Scheme of differential effects underscored by a given receptor and a given agonist in two locations of a cell or in two different 
cells. Depending on the cytocrin pathways/mechanisms (see (25)) engaged after activation of a single receptor and a single pathway (e.g. 
the cAMP-dependent pathway), the effect may be different. Panel A: Biased receptor functionality in a neuron taking into account the same 
agonist and the same receptor located pre- versus postsynaptically. Panel B: Biased receptor functionality in two different cells in which 
the same agonist, the same receptor and the same pathway (e.g. the cAMP-dependent pathway) engages two different cytocrin pathways/
mechanisms.
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As already mentioned, we think that before 
searching/developing biased agonists it is crucial to 
understand what happens when we look at a single 
receptor and a single agonist. The cell response may be 
different in a cardiomyocyte and in a neuron but, is it the 
signaling machinery the same that is engaged in both cell 
types? There is cumulative evidence showing that the 
endogenous agonist (or any standard synthetic agonist) 
may underscore different functional outputs. The scenario 
consists of i) diverse receptor structures/conformations, 
ii) diverse coupling to proteins of the proximal signal 
transduction machinery and iii) diverse cytocrin players. 
In summary, the common mechanisms of biased receptor 
functionality and of biased agonism rely on different 
conformations, on diverse coupling to effector proteins and 
on which are the components of the cytocrin machinery. 
However, biased receptor functionality is a property 
of GPCRs. A given GPCR in a given context has a given 
functionality which is likely expressed by engagement of a 
specific signal transduction component. A single receptor 
in a given cell may be expressed in different structural 
contexts thus giving rise to differential functionalities 
disclosed by the same agonist. A classic example is the 
expression of a receptor in a neuron that may be located 
in the cell body as well as pre- and/or post-synaptically 
(Figure 2). In each location, the endogenous ligand acts on 
a given conformation and leads to different functionalities 
that may or may not have several common  components 
of the signaling/cytocrin machineries. A further relevant 
aspect to consider is whether the transduction machinery 
is precoupled with a given conformation or whether it 
is the stabilization of the conformation that forces the 
engagement of a specific signal transduction. In our 
recent experience, there are GPCRs that are already 
precoupled and just “waiting” for the appropriate agonist 
that stabilizes the overall macromolecular complex and 
leads to a particular signaling output (29).
Indeed, biased agonism is a consequence of the 
diversity of receptor functionalities. Using different 
agonists, one may be able to detect a specific conformation 
of a given receptor in a given context. Also, drug discovery 
programs rely on the biased agonism concept to identify 
drugs with more efficacy and less side effects (Figure 1). 
Gilchrist (2007) was able to concisely convey the idea in 
this sentence written more than a decade ago: “a GPCR 
could have a different pharmacological profile depending 
on which G protein is activated and that the same GPCR 
could have different roles depending on the activating 
molecule as well as the G proteins present in the local 
environment” (30). The statement that the same GPCR 
Figure 3: Scheme of biased receptor functionality. A same receptor (in green) in three different heteromeric contexts in a given system may 
lead to different signaling events using the same agonist. By definition (34), the function of a given heteromer is different of that displayed 
by the constituting receptors when expressed alone (i.e. in monomeric form). Different heteromeric contexts correlate with different 
conformations and may occur even in the same system (a given cell). Conformation of the green receptor depends on interactions with other 
receptors but also on membrane lipid composition, adapter proteins and cellular transmembrane environment. Proteins that interact with 
the GPCR once it is in active form are considered members of the cytocrin machinery.
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could have different roles depending on the G proteins 
present in the local environment, may be elucidated by 
a single agonist and would be holistically considered as 
a biochemical property of GPCRs in a given context, i.e. 
forming part of a functional unit (Figure 3). We favor 
the idea that functional units are supported by specific 
conformations. Conformation of a receptor in a given 
context depends on a variety of factors that include 
membrane lipid composition, adapter proteins and 
cellular transmembrane environment.
The explanation of GPCR-related signaling bias via 
conformation-based mechanism is very robust. We will 
provide some examples to be added to those described 
above. However, a detailed review on the studies of 
this subject is out of the scope of the present article. 
Consistent with structural data on GPCRs in complex 
with G proteins, mutations in intracellular loops lead 
to conformational changes that affect agonist actions. 
Indeed, alanine substitution of amino acids in the 
IL3 loop of the melanocortin-3 receptor (MC3R) does 
not provide constitutive activity while alters receptor 
occupancy. Interestingly, some mutants enhance it and 
others decrease occupancy. Furthermore, mutations also 
modify maximal responses and EC50 values (31). The 
same laboratory demonstrated that a motif, DPLIY in 
helix 8, is important for obtaining a biased response in 
terms of balance between cAMP-related responses versus 
MAPK pathway activation (32). Mutants of the muscarinic 
acetylcholine M2 receptor in a model in which the cell 
context is nullified and the effect of the endogenous 
ligand is minimized, provided “evidence that downstream 
signaling pathways previously considered to be related to 
each other (i.e. receptor phosphorylation, internalization, 
and activation of ERK1/2) can act independently” (33). 
These results constitute proof of constraints that limit the 
active conformation(s) of the receptor. 
Biased receptor functionality: 
examples based on heteromer 
formation
From a rigorous biochemical point of view, a given GPCR 
conformation is due to the constraints imposed by the 
local context, in general terms by the lipid bilayer and, in 
a more specific way, by direct molecular interactions with 
diverse proteins. It is worth repeating that any unbound 
GPCR conformation reflects the context of the receptor, 
i.e. the dependence on the interaction with the cognate G 
protein and on stable interactions with other proteins.
GPCRs are able to form a variety of heteromers that are 
characterized by properties different from those of the 
constituting receptor protomers (34,35). By definition, 
and importantly, by existing evidence, the functionality 
of a GPCR in a heteromeric context is different of the 
functionality in another heteromeric context, i.e. two 
different heteromers in the same cell or in different 
cells display different functionalities in response to 
the same agonist (Figure 3). In summary, one relevant 
property displayed by GPCRs is the coupling to different 
transduction machineries depending on the heteromeric 
context and/or on interactions with other proteins such 
as calcium sensors. It may be such that A receptor or 
AA homodimer couples to a G protein, whereas the AB 
heteromer couples to a different G protein. There is also 
the possibility that a heterotetramer may couple to two G 
proteins (see below). 
There are multiple examples of differential 
functionality due to receptor heteromerization. To us one 
of the most relevant was reported by (36). They used the 
dopamine D2 receptor long form and specific mutants 
to demonstrate that the functionality of the D2 receptor 
depended on the interaction with the cannabinoid type 
1 receptor (CB1R). Further data on this interaction was 
provided years later by our laboratory (37). Relevant 
in this example is the differential functionality due to 
isoforms of the receptors; for the D2 receptors two forms 
have been identified and characterized, the short and 
the long forms, whose mature mRNAs differ in one exon 
which results in  a different length of the 3rd intracellular 
loop of the receptor (38-40). It is likely that, if not all, many 
members of the GPCRs family display isoforms whose 
functionality in response to the endogenous agonist will 
be, quite likely, different. Another striking example is 
reflected by the differential functionality when dopamine 
D1 and D2 receptors do form heteroreceptor complexes. 
Whereas dopamine leads to increases in cAMP, via D1 
receptors, and to decreases in cAMP, via D2 receptors, the 
neurotransmitter leads to increases in cytosolic calcium 
via D1-D2 heteroreceptor complexes. These results indicate 
that the D1 receptor couples to Gs, the D2 receptor couples 
to Gi  and the D1-D2 heteromer to Gq (41–43). 
The ghrelin receptor is among the few for which a full-
length functional form and a truncated non-functional 
(likely regulatory) form result from alternative splicing. 
Both have been identified and characterized under 
different physiological conditions and also in cancer 
(44–48). Pathogenicity mechanisms may be mediated 
by functionality regulation via heteromers formed by 
the two proteins resulting from alternative splicing. 
Angiotensin II type 1 and CB1 receptor heteromerization is 
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involved in the abnormal function of angiotensin II after 
ethanol consumption. Authors conclude that their results 
“provide a molecular basis for the pivotal role of heteromer-
dependent signal integration in pathology” (49).
Another striking  example is provided in a recent 
report that demonstrates that binding and signaling of 
adenosine A2A receptors are regulated by expression of 
adenosine A2B receptors. Remarkably, the full signaling of 
the A2A receptor is progressively decreased and becomes 
virtually negligible when the A2B receptor is expressed 
and A2A-A2B heteroreceptor complexes are formed (50). In 
practice, A2A receptor-mediated signaling is blocked by the 
presence of the A2B receptor and the formation of A2A-A2B 
receptor heteromers. 
Years ago, it was demonstrated that signaling 
properties of a given GPCR heteromer depend on its 
quaternary structure (37). We have recently proposed the 
quaternary structure of a GPCR heteromer in complex 
with G proteins (51,52). The most abundant species 
in receptors co-expressed in a heterologous system is 
the A1-A2A heterotetramer (2:2 stoichiometry leading 
to a heterotetramer formed by two homodimers). 
The GPCRs arrange into a rhombus-shaped tetramer 
coupled to one Gs and one Gi protein. In summary, the 
differential receptor functionality in this specific case 
results from Gi-directed signaling at low concentrations 
of endogenous agonist, adenosine, and a Gs-directed 
signaling at high concentrations of the purine nucleoside. 
The mechanisms underlying these completely opposed 
signaling (and regulatory) outputs are quite noteworthy. 
While the structure of the macromolecular GPCR/G 
protein complex is fairly symmetric, the signal arising 
from this adenosine concentration sensor is asymmetric 
(either Gi- or Gs-mediated).  The adenosine A1 receptor has 
higher affinity for adenosine than the A2A receptor. Then, 
at low concentrations A2A receptor remains inactive, while 
the A1 receptor is activated and Gi signaling occurs; the 
A2A receptor only gets activated when adenosine levels 
rise. Thus, enhanced adenosine production is able to 
theoretically activate the two receptors. However, in 
such conditions only A2A-mediated Gs signaling occurs. 
This fact is due to intratetramer-mediated blockade of Gi 
function. Such unique mechanism by which Gi is unable to 
activate occurs because there is an “asymmetry” imposed 
by the 122-amino-acid long C-terminal tail of the human 
A2A receptor (the C terminal domain of the A1 receptor 
is very short). Receptor functionality relates to agonist 
concentration and only depends on two parameters: the 
particular structure of the GPCR heteromer and the A1 
versus A2A differential affinity for adenosine. It should 
be noted that biased functionality disclosed by receptor 
activation in the A1-A2A GPCR heteromer does not require 
different agonists leading to diversified signals. Surely, 
biased agonism may be tested on individual receptors or 
in tetrameric functional units to provide new molecules 
to combat specific diseases, which constitutes the 
pharmacology therapy-oriented consequence of a 
biochemical/structural property. 
Biased receptor functionality is also detectable as a link 
to the MAPK pathway when heteromerization of dopamine 
D1 and histamine H3 receptors occurs. This results, in both 
a heterologous system and primary cultures of neurons, 
have shown that D1-H3 receptor heteromers are needed 
for histamine to produce the activation of the MAPK 
pathway. Activation of individual receptors does not lead 
to significant stimulation of the pathway by histamine. 
This specific biased receptor functionality occurring in a 
motor-control area of the brain, striatum, has a relevant 
physiological consequence as it happens in D1-containing 
but not in D2-containing neurons, i.e. it is specific for 
cells expressing D1, H3 and D1-H3 heteromers (53,54). 
Accordingly, histamine activates the MAPK pathway in 
the so-called direct pathway (of motor control) but not in 
the indirect pathway; D1 and D1-H3 receptor heteromers are 
expressed in neurons of the direct but not of the indirect 
pathway. Opioid receptors are also able to heteromerize 
and, importantly, desensitization of opioid receptors in 
an heteromeric context is completely different than that 
in absence of heteromerization (55). The result is relevant 
because opioids are drugs whose efficacy depends on 
receptor desensitization. 
Dopamine D1 receptors may heteromerize with ghrelin 
GHS-R1a receptors and such heteromerization leads to a 
shift in the signaling induced by the hunger hormone, 
ghrelin. In fact, the canonical ghrelin activation leads to the 
engagement of Gq signaling and, therefore, to intracellular 
calcium mobilization. In some circumstances, it has been 
described that ghrelin receptors may couple to Gi (56). 
However, in an heteromeric context ghrelin may couple to 
Gs. The most reasonable hypothesis of such finding is that 
individual ghrelin receptors couple to Gq or Gi, but that 
in cells expressing D1-GHS-R1a heteroreceptor complexes 
the hormone produces an increase in cAMP levels. There 
is a Gq/Gi bias of the ghrelin receptor that in the presence 
of the dopamine receptor is converted into a Gs bias. It 
is likely that the D1-GHS-R1a receptor heteromer is only 
coupled to Gs. In summary, depending on the heteromeric 
context a given hormone may lead to increases in [Ca2+] 
or to increases in [cAMP]. Importantly, the Gs coupling to 
the ghrelin receptor was identified in primary cultures of 
striatal neurons (56), i.e. it has physiological relevance. A 
further proof of physiological meaning was the absence of 
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any Gs-mediated signal when neurons from another brain 
area (hippocampus) were treated with ghrelin (56).
So-far the number of identified GPCR heteromers is 
>500; a platform that displays all of them also showing the 
ad hoc references is found in: www.gpcr-hetnet.com (see 
description of the platform in (57)).
Biased receptor functionality and 
biased agonism: mechanisms based 
on cytocrin pathways, β-arrestin 
recruitment and signaling regula-
tion by calcium
As commented above, activation of a given receptor may 
lead to differential cytocrin outputs, even in the same 
cell. Although from a pharmacological point of view it 
is convenient to assume that functional selectivity is 
disclosed using different agonists, the root of biased 
receptor functionality is less pharmacological and more 
biological/biochemical. The result of receptor activation 
by an endogenous agonist is not only a consequence of 
signal transduction but of the components of the cytocrin 
machinery, which are not directly related to GPCRs 
themselves (Figures 2-3). Actually, β-arrestins cannot be 
considered members of the signal transduction machinery 
but of the cytocrin machinery. β-arrestins may be more 
pleiotropic than other cytocrin players but they do not 
directly interact with “resting” GPCRs. It is not until the 
receptor is activated that these proteins are recruited and 
participate in the overall output. Just taking into account 
the kinetics of recruitment (e.g. due to different affinity 
for the same receptor conformation), biased agonism 
occurs. Indeed, it is often forgotten that affinities depend 
on association and dissociation constants and they 
indeed affect the kinetics of overall signal transduction. 
Kinetics of β-arrestin recruitment is a variable that not 
only depends on the receptor and the agonist but on the 
cytocrin components/effectors. 
Biased receptor functionality displayed by a given 
cell (preferentially the cell targeted in a given disease) 
may provide clues on underlying mechanisms and/or to 
correlate stabilization of particular GPCR conformations 
with particular cytocrin pathways and signaling outputs. 
Biased receptor functionality may be disclosed by a given 
agonist (preferentially the endogenous one) when tested 
in different cells and/or in a given cell type in different 
locations/contexts. How may this be possible? It could be 
that, different affinity states may exist for a given receptor, 
each of them leading to a different transduction outputs. 
One example of GPCR with different affinity states in 
binding of a given radioligand agonist is provided by 
the adenosine A1 receptor (58–61). Interestingly, the 
high affinity state was assumed to be G-protein-coupled 
while the low affinity one was assumed to be G-protein-
uncoupled. A second, more interesting possibility, 
is differential functionality of a given GPCR derived 
from interactions engaged by second messengers not 
directly related to the signaling of the GPCR that is being 
studied. It should be added that affinity may also vary in 
a heteromeric context; the binding of agonists and the 
G-protein-coupling vary when the A1 receptor interacts 
with β-adrenergic receptors (62). It is relatively common 
that the affinity of ligand binding to a given receptor 
varies in a heteromeric context, for instance in the case of 
opioid receptor heteromers (63).
Not only the interaction with components of the 
signaling machinery but the intracellular concentration 
of relevant compounds, second messengers in the case 
of GPCRs, may lead to diverse receptor functionality. 
A recent example is provided by the CB1R which is 
canonically coupled to Gi and, therefore, its activation 
leads to a decrease in the level of intracellular cAMP. This 
receptor is the most abundant GPCR in neurons of the 
central nervous system in which calcium is a key factor 
in neurotransmission. Upon interacting with calcium 
binding proteins and upon increases of intracellular 
calcium, activation of the CB1R does not lead to Gi 
engagement and the output may even seem as if the GPCR 
is coupled to Gs (64). In this case, a given agonist could 
cause decreases or increases of cAMP depending on the 
intracellular calcium levels. Once more, biased receptor 
functionality is disclosed by using a single agonist. 
Summing up, GPCR functionality depends on the overall 
context involving calcium concentration and calcium 
binding protein expression. In fact, GPCR functionality is 
regulated by the calcium sensors expressed in a given cell 
and by the dynamic GPCR/calcium sensor interactions 
that are dependent in turn on the concentration of calcium 
(64). Another example would be the case in which calcium 
sensor expression changes. Thus, GPCR functionality will 
be different in resting versus reactive  microglial cells  due 
to differential GPCR-protein interactions (64,65). This 
type of regulation may occur in the case of heteromers. 
In fact, the first report on regulation of GPCR heteromers 
by calcium and calcium sensors showed an interaction 
between calmodulin and the C-terminal domain of the 
adenosine A2A receptor. Via calmodulin, conformational 
changes triggered by calcium modulate MAPK signaling 
induced by activation of adenosine A2A and dopamine D2 
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receptors within the “context” of A2A-D2 heteromerization 
(66). 
Conclusion
Biased agonism has a clear objective, which is of 
pharmacological nature, i.e. given a therapeutic target 
(a GPCR), one ligand may be better than another and 
differences may be disclosed by measuring the bias factor. 
However, by the new concepts presented in this mini-
review, the right model and the right conditions must be 
carefully selected for making the selection of the right 
biased ligand. In particular, the well-known but often 
forgotten biased receptor functionality should be taken 
into account. In practice, the GPCR drug development 
field must consider that finite conformations exist in 
a given cell, that each conformation reflects a given 
structure involving the receptor and directly interacting 
partners, and that cytocrin components must be taken 
into consideration. The appropriate therapeutic action 
likely depends on the biased receptor functionality in 
the target cell whereas detection of the ad hoc biased 
agonist comes later. Hence, agonist bias factors calculated 
using heterologous cells may not be as successful in drug 
discovery as a priori hypothesized.
We argue that conformations are finite and that 
the cell surface cannot be observed as a monotonous 
landscape allowing multiple GPCR conformations. 
Therefore, we consider that biased receptor functionality 
could be first disclosed by a single agonist (preferably the 
endogenous one) and that the landscape is constituted 
by different conformational receptors each having its 
own functionality. A corollary would be that receptor 
functionality will condition the results of biased agonism, 
both in terms of the value of bias factors and of engagement 
of the most appropriate signaling pathway. 
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